Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01293981 · ClinicalTrials.gov registry record
Radiographic and Clinical Outcomes of PureGen in Posterior Lumbar (PLIF) and Transforaminal Interbody Fusion (TLIF)
A clinical trial, sponsored by Alphatec Spine.
- Terminated
- Registry status
- 6
- Enrollment target
NCT01293981: Clinical Trial study, sponsored by Alphatec Spine.
NCT01293981 is a clinical trial that was terminated before completion, run by Alphatec Spine. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01293981 was terminated before completion, sponsored by Alphatec Spine.
- TERMINATED
- Registry status
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of PureGen Osteoprogenitor Cell Allograft in patients undergoing Posterior Lumbar or Transforaminal Interbody Fusion.
Primary Outcome
Proportion of subjects with fusion at the 24 month visit
Interventions
- BIOLOGICAL PureGen Osteoprogenitor Cell Allograft
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-02 |
Why NCT01293981 stopped before completion
NCT01293981 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which PureGen Osteoprogenitor Cell Allograft is the first listed.
NCT01293981 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01293981 about?
NCT01293981 is a clinical study titled "Radiographic and Clinical Outcomes of PureGen in Posterior Lumbar (PLIF) and Transforaminal Interbody Fusion (TLIF)". The purpose of this study is to assess the safety and efficacy of PureGen Osteoprogenitor Cell Allograft in patients undergoing Posterior Lumbar or Transforaminal Interbody Fusion.
What is the current status of trial NCT01293981?
This trial is currently terminated. The enrollment target is 6 participants. The study started on 2011-02.
What interventions are being tested in trial NCT01293981?
The interventions under investigation include: PureGen Osteoprogenitor Cell Allograft (BIOLOGICAL).
Who is sponsoring clinical trial NCT01293981?
This trial is sponsored by Alphatec Spine, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia